Solid Biosciences

SOLID BIOSCIENCES INC

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Lab.Pharma.Pharmeuticals

Analyst Color

Biotech

News

Downgrades

Health Care

Analyst Ratings

Trading Ideas

General

SLDB

SRPT

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand


In another tragic incident, Sarepta Therapeutics (NASDAQ:SRPT) saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute liver failure

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

Konskie,,Poland,-,February,24,,2024:,Sarepta,Therapeutics,Company,Logo

Pre-Market Outlook

Markets

Movers

GROY

IONQ

KULR

OMDA

RGEN

TNGX

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Solid Biosciences Inc

Press Releases

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Management

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Earnings

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

ABOS

CLYM

LENZ

VERV

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Aura Biosciences

Crescent Biopharma

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

CytomX Therapeutics

Emergent BioSolutions

Erasca

Heron Therapeutics

Humacyte

ITeos Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Oruka Therapeutics

Precigen

Prime Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Vigil Neuroscience

Citigroup

HC Wainwright & Co.

JMP Securities

Cantor Fitzgerald

Chardan Capital

Comments

Solid Biosciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell